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Summary Randomised trials have demonstrated that pulmonary rehabilitation
(PR) can improve dyspnoea, exercise tolerance and health related quality of life.
Rehabilitation has traditionally been provided in secondary care to patients with
moderate to severe disease. Current concepts are however recommending that
it should be delivered in a primary and community care setting for patients with
milder disease. There are several opportunities for spreading the word for PR in
primary care. One of these is to improve access to PR for all those disabled by
their disease by the increase of community schemes and one such scheme being
utlised in Canada is reviewed.
The essential components of PR include behavior change, patient self-
management and prescriptive exercise. In the last decade new strategies have
been developed to enhance the effects of exercise training. An overview of these
new approaches being an adjunct to exercise training is reviewed. Although the
role of exercise training is well established, we are only just beginning to appreci-
ate the importance of behavior change and patient self-management in contribut-
ing to improved health and diminished healthcare resource utilisation.
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We have also reviewed the evidence for benefit of ambulatory oxygen, carried on
the person during exercise or activities of daily living. Potential benefits include an
improvement in task performance, a reduction in task-associated breathlessness,
a more general improvement in quality of life or perhaps even a longer survival.
Since the provision of oxygen services is determined by the nature of the health
care system, we have provided two views of the issues from the United Kingdom
and the United States.
© 2008 Elsevier Ltd. All rights reserved.
Introduction
Randomised trials have demonstrated that respi-
ratory rehabilitation can improve dyspnoea, exer-
cise tolerance and health related quality of life.1---4
As a result, the current recommendations in the
GOLD guidelines are that COPD patients at all
stages of the disease benefit from exercise training
programmes.5 In addition, the NICE guidelines state
that rehabilitation should be considered at all stages
of disease progression when symptoms and disabil-
ity are present and not at a predetermined level of
impairment. The threshold for referral would usu-
ally be breathlessness equivalent to MRC dyspnoea
grade 3.6
Rehabilitation has traditionally been provided in
secondary care during the stable phase of the dis-
ease to patients with moderate to severe disease.
Current concepts are however recommending that
it should be delivered in a primary and community
care setting for patients with milder disease. This
in itself provides many challenges including lack of
primary care knowledge, a lack of resources and fa-
cilities and ambivalence about early detection of
COPD. For example, in a telephone questionnaire
of GPs and practice nurses, 61% of respondents con-
firmed that they did not understand what was in-
volved in pulmonary rehabilitation and 51% did not
know whether it had been shown to be effective in
managing COPD (BTS consortium survey).7
Why is rehabilitation important?
It has been shown that high levels of physical activ-
ity (equivalent to >60 minutes a day) substantially
reduced the risk of readmission to hospital for an
exacerbation by almost 50%.8 In addition, two vari-
ables including a high usual physical activity and
higher score on the physical domain of quality of
life, significantly reduced the risk of readmission.9
Not only did physical activity prevent readmission
to hospital but it was also shown to significantly re-
duce mortality.10 In addition, the effects of an early
community based pulmonary rehabilitation (PR) pro-
gramme after hospitalisation for acute exacerba-
tions of COPD was evaluated in a single centre, ran-
domised controlled trial.11 An eight week, PR pro-
gramme for outpatients, started within 10 days of
hospital discharge, compared to usual care showed
that early PR resulted in statistically and clinically
significant improvements in exercise capacity mea-
sured by the incremental shuttle walk test and
health status.
There are several opportunities for spreading the
word for PR in primary care. One of these is to im-
prove access to PR for all those disabled by their
disease by the increase of community schemes. One
such scheme being utlised in Canada is detailed be-
low.
“Row your own boat programme”
In Canada, only 1% of all patients with clinically im-
portant COPD currently have access to PR, includ-
ing hospital, community, or home based programs,12
despite the strong endorsement of such programs
in the professional guidelines of the Canadian Tho-
racic Society.13 Moreover, it is unknown how many
of these patients complete and maintain their reha-
bilitation program.
The essential components of PR include behav-
ior change, patient self-management and prescrip-
tive exercise.13 The mainstay of rehabilitation is the
maintenance phase and although the role of exer-
cise training is well established, we are only just
beginning to appreciate the importance of behavior
change and patient self-management in contribut-
ing to improved health and diminished healthcare
resource utilisation.
In keeping with many other jurisdictions, there
are many issues with the Canadian Health Care De-
livery System including; a focus on medical man-
agement rather than self management, the location
and availability of services and emphasis on physio-
logic outcomes typically associated with acute care,
rather than outcomes such as quality of life and self
efficacy more typically associated with chronic con-
ditions. In short, the system in which we practice,
in common with many other systems, is designed to
provide care for those who are acutely ill, lacks the
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infrastructure to manage chronic illness and must
evolve if appropriate care is to be made available
for the very large number of individuals with chronic
conditions.
Without substantial change our current health-
care system will remain incapable of managing
chronic respiratory disease. What is needed is con-
sistent, community based care to enable people
with chronic disease to stay out of hospital and
live independent, productive lives. In Calgary, the
Chronic Care Model developed by the MacColl Insti-
tute for Healthcare Innovation --- the Seattle Model)
has been implemented 14,15 which focuses on “Best
COPD Care”, in the context of chronic disease man-
agement (CDM), which includes several other diag-
nostic categories. This has allowed us to share a
common infrastructure and to implement commu-
nity based CDM for large numbers of COPD patients
while simultaneously reducing costs to the health
care system.
In this COPD care model, the patient is looked af-
ter by their family physician together with a shared
care team, with access to other community ser-
vice providers as well as to the acute care sector.
Overseeing this is a multidisciplinary team of COPD
experts, who provide research and outcome man-
agement, health provider education, high risk dis-
ease management and local clinical practice guide-
lines. The model has four components which in-
clude: system support by electronic information
systems, family physician support and community
based rehabilitation programs that emphasize be-
havior change, disease specific self management
and prescribed exercise, as well as close follow-up
of high risk patients.
It has been recognized that patients partici-
pating in COPD self management, compared to
usual care, have decreased COPD exacerbations,
decreased emergency room visits and decreased
hospitalization.16 They also have improved HRQL,
decreased dyspnea, improved self efficacy, in-
creased knowledge and increased exercise toler-
ance. The strengths of the CDM model are that it is
evidence based, comprehensive and addresses gaps
in our system. Moreover, it is community based and
easily transferable to other jurisdictions. It is an af-
fordable, good return on investment. We based the
“Row Your Own Boat” component on the “Living a
Healthy Life with Chronic Conditions” model pio-
neered by Dr. Kate Lorig and her colleagues at Stan-
ford University.17
The program is open to anyone with a chronic ill-
ness and is taught in small groups by lay leaders who
receive standardized training from a highly struc-
tured teaching protocol (Table 1). The core assump-
tions of this program are that patients with differ-
Table 1 Characteristics of Program
• A generic program open to anyone with a long
term illness• Taught in small groups• 6 weeks for 2.5 hours per week• Taught by lay leaders who receive standardized
training• Highly structured teaching protocol• Standardized participant materials• Simple stepwise approach
ent chronic diseases have similar self-management
problems and disease-related tasks. Patients can
learn to take responsibility for the day-to-day man-
agement of their disease(s).
The “Row Your Own Boat” program is a paradigm
shift for individuals with chronic disease as it is
led by individuals with chronic disease rather than
healthcare professionals. It differs from current pa-
tient education which usually comprises a series of
didactic lectures, in that patients learn to manage
life with their chronic disease, increase life skills
and self-confidence as well as to problem solve us-
ing specific tools. Each patient takes ownership of
their own health status. The content is based on role
modeling and emotional management as opposed to
disease knowledge. The leader is a guide and role
model encouraging peer to peer learning. The CDM
mission is to provide the infrastructure---both peo-
ple and processes---so that individuals with chronic
illness can live well and stay out of the hospital (Ta-
ble 2).
Initial program benefits have included improved
health behaviors, health status, and health care
Table 2 Core Assumptions
• Patients with different chronic diseases have
similar self-management problems and
disease-related tasks• Patients can learn to take responsibility for the
day-to-day management of their disease(s)• Patient self-management education should be
inexpensive and widely available• Trained lay persons with chronic conditions can
effectively deliver a structured patient
education program• Confident, knowledgeable patients practicing
self-management will experience improved
health status and use fewer health care
resources
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utilization,18,19 with evidence that when programs
are taught by lay persons with chronic disease, pa-
tients have a higher attendance rate, do more, have
better health status and self efficacy and more im-
portantly, maintain these behavior changes, com-
pared with education by healthcare professionals.
It is clear that further implementation must be pre-
ceded by more detailed outcomes research that em-
ploys randomized controlled trials with longitudi-
nal designs emphasizing valid, evaluative and inter-
pretable outcomes.
In summary, this new model of PR has the poten-
tial to be the next step forward in thinking outside
of the box of the acute care management paradigm.
New strategies to enhance the effects of
exercise training
In the last decade new strategies have been devel-
oped to enhance the effects of exercise training. An
overview of these new approaches being an adjunct
to exercise training is found below.
Inspiratory muscle training (IMT)
The recent published statement of the ATS/ERS on
pulmonary rehabilitation concluded in their prac-
tice guidelines that IMT may be considered as an
adjunct in rehabilitation programs, primarily in pa-
tients with suspected or proven muscle weakness.20
Two types of inspiratory muscle training (IMT) are
known: strength or endurance. For strength training
the subject makes repeated inspiratory and expi-
ratory manoevres against a closed mouthpiece. En-
durance training has used three methods until now:
isocapneic hyperpnea, resistive loading or pressure
threshold loading.
Inspiratory muscle training alone
A recent meta-analysis has shown that IMT does im-
prove strength and endurance capacity, whereas the
sensation of dyspnoea significantly decreases.21 In
addition, functional exercise capacity tended to be
an additional effect of IMT, alone and as an adjunct
to general exercise training, without reaching sta-
tistical significance. It was further shown that inspi-
ratory muscle weakness as assessed by a maximal
inspiratory capacity (PImax) < 60 cm H2O, plays a
key-role in the efficacy of IMT.
Inspiratory muscle training added to
exercise training
Some studies have evaluated whether IMT repre-
sents a useful addition to exercise training. While in
some studies the addition of IMT did improve PImax
and exercise capacity compared with exercise train-
ing alone22---24 it did not result in further improve-
ment in exercise performance compared to exercise
training alone. 25,26 In addition a systematic review
also didn' t find conclusive evidence for adding IMT
to exercise alone.27
Supplemental oxygen during exercise
training
It has been postulated that administering oxygen
during exercise training will, by alleviating the
exercise induced hypoxemia, allow the patient to
reach a higher training intensity than they would
otherwise achieve while breathing room air. Un-
fortunately, the results of 2 randomised controlled
trials were disappointing. In one study, 24 patients
with COPD (mean FEV1 34% pred.) who increased
their alveolar-arterial gradient for oxygen during
exercise by more than 15 mm Hg were randomly
allocated to breathe either room air or oxygen at
4 L/min during exercise training.28 After 10 weeks,
walking, stair-climbing, weightlifting, and health
status increased in both groups with no significant
between group differences. In another study, 25
patients (mean FEV1 30% pred.) were randomised
to a similar training protocol.29 After 6 weeks of
training dyspnea improved in those trained with
oxygen but there was no between group differ-
ence in shuttle walking distance, or measures of
health status. In contrast to the previous studies,
Emtner et al. investigated the influence of oxygen
supplementation in non-hypoxaemic patients.30
Oxygen supplementation allowed a higher training
intensity and enhanced exercise performance in the
laboratory setting probably because of a reduced
ventilatory response. Recently, it was suggested
that we have to look more in detail at the effects
of oxygen, as it seems that supplemental oxy-
gen prevents exercise induced oxidative stress in
normoxemic muscle wasted patients.31
Ventilatory support during exercise
The severe airflow limitation that characterizes ad-
vanced COPD is frequently associated with hyperin-
flation, especially during exercise when the absence
of any flow reserve even at rest, requires the sub-
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ject to breath at a higher lung volume in order to
meet the ventilatory requirements of exercise. This
in turn increases the work of breathing, initially to
overcome the intrinsic positive end expiratory pres-
sures (subjects may have to generate a negative
pressure of ---5 to ---15 cmH2O before any inspiratory
flow occurs). As the increased ventilatory require-
ments of exercise are difficult to sustain, clinicians
are challenged to identify approaches that might
improve the neuro-mechanical linkages of respira-
tion by assisting with the mechanical output using
ventilatory support.
Ventilatory support during exercise may de-
crease dyspnea and improve exercise among pa-
tients with COPD but current evidence comes from
pilot studies.32---34 Therefore widespread use during
training requires larger clinical trials in order to
identify the most effective approaches to ventila-
tory support during exercise training. Further stud-
ies are also needed to determine the possible ef-
fects of chronic ventilatory support in addition to
training.
In a recent study the addition of short-term NIPPV
at home (median 2.1 hours/day, range 0---11.4) to
an out-patient rehabilitation program improved the
shuttle walking distance and quality of life among
normocapnic patients (mean PaCO2 44 mmHg) to a
greater extent than did rehabilitation alone.35 Re-
markable is the fact that 50% of the patients used
NIPPV for less than 2 hours which is a short time. It
is interesting to see what the impact of NIPPV is in
hypercapnic patients. Until now no study has inves-
tigated this issue in this specific group of patients.
Neuromuscular electrical stimulation
Neuromuscular electrical stimulation (NMES) is char-
acterized by a low-volt stimulation of the contrac-
tion of peripheral muscles trying to improve its func-
tion. It has been tested in patients with severe pe-
ripheral muscle weakness or in bed bound patients.
Until now 4 small controlled studies have used this
technique in patients with COPD.36---39In the study
of Neder, after a 6-week home based programme,
patients showed significant improvements in mus-
cle function, maximal and endurance exercise toler-
ance, and dyspnoea.36 In addition the improvements
in muscle performance and exercise capacity after
NMES correlated well with decrease in perception
for leg effort. In another similar study, a significant
improvement in both quadriceps and hamstrings
muscle strength was found compared to the sham
group.37 While there was no change in lung func-
tion and peak workload, the training group showed
a significantly better shuttle walking distance. Zan-
otti et al. investigated the additional benefits of
NEMS op top of exercise training in bed bound pa-
tients receiving mechanical ventilation because of
chronic respiratory failure due to COPD.38 The to-
tal length of training was 28 days. The addition of
NEMS resulted in an increase in muscle strength,
a reduced respiratory rate and a decrease in the
number of days needed to get out of bed on the
chair. Probably NMES works because there is less
ventilatory stress during NMES. A recent study of
Vivodtzev showed that the combination of exercise
training and NEMS lead to a greater improvement
in quadriceps strength and dyspnoea during perfor-
mance of daily tasks in patients with very severe
COPD with low body mass index.39 Despite the pos-
itive effects the studies are carried out in a small
number of patients and not all studies included a
sham treatment. Currently we do not know what
type of patients might have the most benefit from
it. The practice guideline of the ERS/ATS suggests
that NEMS may be a beneficial adjunct therapy next
to exercise training in patients with COPD especially
in those who have severe muscle weakness.20
Future research
It is clear that not all mentioned interventions are
of benefit to every patient with COPD. New stud-
ies should be set up in carefully selected patients to
define which patient will benefit from what therapy.
New areas for research, though highly speculative,
are investigating the additional benefits of erythro-
poitine in anaemic patients or if some patient might
benefit from anti-oxidant therapy. Finally, more re-
search is needed to investigate how the initial ef-
fects can be maintained.
Does ambulatory oxygen have intrinsic
merit?
Ambulatory oxygen is carried on the person dur-
ing exercise or activities of daily living. Potential
benefits include an improvement in task perfor-
mance, a reduction in task-associated breathless-
ness, a more general improvement in quality of life
or perhaps even a longer survival. Ambulatory oxy-
gen can be considered in combination with station-
ary oxygen therapy or by itself when only activity-
induced hypoxia is present. Its benefits should be
considered against the disadvantage of the require-
ment to carry the delivery system. We have re-
viewed the evidence for benefit of ambulatory oxy-
gen used alone and as an adjunct to stationary oxy-
gen. Since the provision of oxygen services is deter-
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mined by the nature of the health care system, we
have provided two views of the issues surrounding
ambulatory oxygen from the United Kingdom (UK)
and the United States.
The view from the UK
The proper provision of ambulatory oxygen has been
seen in the UK as an important reflection of the
quality of care for people with long-term lung dis-
ease. In the case of COPD, the availability of am-
bulatory oxygen ranks alongside pulmonary rehabil-
itation and nebuliser provision as a marker of good
clinical care. Consequently the ability to prescribe
appropriate ambulatory oxygen is seen by patient
groups and professional organisations as an impor-
tant issue.40,41
Does it work?
Supplementary oxygen improves cycle ergometry
performance in the laboratory and reduces task-
associated dyspnoea.42 However oxygen adminis-
tered after exercise does not increase the rate
of recovery of dyspnoea in spite of reducing dy-
namic hyperinflation.43 A number of short-term tri-
als demonstrate that ambulatory oxygen can im-
prove walking performance. These results have re-
cently been amalgamated in a Cochrane systematic
review.44 This shows that benefits in the order of
a few metres (mean 21m) can be achieved in walk-
ing tests by carrying ambulatory oxygen. Endurance-
type walking tests appear to be most sensitive to
change. The authors of the Cochrane review suggest
that an appropriate assessment for ambulatory oxy-
gen would include an endurance walking test and a
measurement of isotime dyspnoea.
Is it worth the weight?
The available evidence suggests that carrying oxy-
gen on the person is associated with a small im-
provement in exercise performance which is gener-
ally below the level of clinical significance recog-
nised for the six-minute walk test. In the longer
term, ambulatory oxygen may improve health status
but recognition of a small improvement in exercise
performance is not associated with long-term con-
cordance. In fact most people who are issued with
long-term ambulatory oxygen use it fairly little.45
A recent double-blind controlled trial from
Canada examined the effect of ambulatory oxygen
on exercise performance, health status and cylin-
der usage over three four month periods in patients
already on LTOT.46 Uptake of cylinder usage in the
oxygen arm was meagre and similar to air cylinders.
The trial was stopped prematurely because the oxy-
gen had no clear benefit over cylinder air in addition
to stationary oxygen. This concurs with the recent
evidence on short burst oxygen suggesting that the
effect on dyspnoea may be due to gas flow on the
face rather than the effect of oxygen itself.47
Assessment for ambulatory oxygen
As far as we know, there is no specific survival ad-
vantage to using ambulatory oxygen in addition to
stationary oxygen. It is also clear that many people
do not use significant amounts of ambulatory oxy-
gen or may take time to learn how to use it. Those
who do use the oxygen or subsequently increase
usage are presumably receiving some benefit from
it. A short-term response to an exercise test does
not appear to predict long-term concordance and
therefore does not have any predictive value. In the
past, an improvement of 10% in an exercise test has
been recommended but this would seem to have no
validity.48 In some countries, ambulatory oxygen is
issued to all patients on LTOT who demonstrate ex-
ercise induced de-saturation and some recommend
that a response to an exercise test is required.
The British Thoracic Society Working Party on
home oxygen has taken a different approach in line
with the recent evidence. In this case the purpose
of the exercise test is to confirm the presence of de-
saturation and to set a flow rate for prescription. It
is recommended that eligible, consenting patients
are offered a trial of ambulatory oxygen over a two-
month period. If there is subjective benefit and the
cylinders are used, then the patient continues on
ambulatory oxygen. If it is not taken up then the
patient can be issued with a single cylinder for oc-
casional portable use (Fig 1).
A View from the United States
Do a larger or a smaller number of patients need
ambulatory oxygen?
In the United States, the use of LTOT is heavily
influenced by the legislative and regulatory en-
vironment. At first glance, the situation appears
quite favourable: no patient meeting criteria is
denied oxygen therapy and overall funding is good.
A more detailed look however reveals real problems
and the possibility for marked deterioration in the
near future.
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Figure 1 Flow chart for the assessment for ambulatory oxygen from the Clinical Component for the Home Oxygen
Service in England and Wales.
We can roughly characterize oxygen utilization in
the United States, though precise figures are hard
to come by. In the order of 1 million people receive
LTOT and about 85% of these have COPD.49 Medicare
is the major funder of oxygen therapy. The annual
cost of LTOT is estimated at $1.2 billion and one
estimate puts this at 18% of all health care expendi-
tures for COPD50, a staggeringly high fraction when
one considers that only a small fraction of COPD pa-
tients receive LTOT. Remarkably, the per capita us-
age of LTOT has been reported to be roughly 8-fold
higher than in any other country.51
It is difficult to explain the high utilisation of
LTOT in the United States as there is no evidence
that diseases yielding chronic hypoxemia are sub-
stantially more prevalent. It would be an unlikely
postulate that US physicians are particularly more
adept at detecting diseases requiring LTOT. It seems
plausible that, in large part, this high utilization re-
lates to the regulations dictating oxygen prescrip-
tion. Oxygen prescribing procedures are, arguably,
rather lax and most prescriptions are generated
by primary care practitioners and not by pulmo-
nologists. Once prescribed, oxygen suppliers have
a strong incentive to continue to supply oxygen
therapy. Most oxygen is prescribed in the course of
disease exacerbation; re-evaluation after patients
resume their stable state is often not performed.
Though firm estimates are not available, small sur-
veys indicate that on re-evaluation a large fraction
of LTOT patients do not meet criteria for oxygen
therapy initiation.52 (There is a theory that LTOT ex-
erts a reparative effect on the lung' s ability to oxy-
genate and that this reparative effect will be lost if
oxygen therapy is removed53; this theory, however,
remains unproven.) A demonstration project to de-
termine the effect of more rigorous recertification
procedures has been proposed.54
Suppliers provide oxygen therapy to customers
and most are reimbursed by Medicare in a modal-
ity neutral manner. That is, a certain amount of
money is paid monthly for patients receiving a sta-
tionary supply (currently about $220) and a small
supplement is paid for patients who require ambu-
latory supplies (currently about $32). This money is
paid irrespective of the devices used; a substantial
fraction of patients receive stationary concentrators
plus an E-cylinder (mounted in a wheeled cart) for
ambulation. Competitive pressures among suppliers
are supposed to yield better (and more expensive)
ambulatory oxygen sources for those patients able
to make good use of them. The extent to which this
actually occurs is hard to determine.
Budgetary limitations and rapidly escalating
numbers of LTOT patients have led to attempts to
reign in costs. Since 1998, a number of reductions
in the monthly payment to suppliers has ratch-
eted down reimbursement. Competitive bidding
has been proposed to enable selection of oxygen
providers regionally and this scheme is scheduled
to be phased in. This plan is proceeding despite
the fact that a demonstration project yielded
clear evidence that this process limited access to
ambulatory equipment. The past year has seen
further developments. The Deficit Reduction Act of
2005 featured a requirement that the monthly pay-
ments for oxygen “rental” could not extend beyond
36 months for an individual patient; thereafter
ownership of the equipment would be transferred
to the patient and monthly payments would cease.
The details of how this will be implemented were
provided in a long Federal Register entry dated
August 3, 2006. A new system of modality-specific
payments is proposed, the implications of which
are not clear as of this writing.
It might be asked why the provision of LTOT is
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in such chaos in the United States. At least part
of the answer, it might be argued, is that the
scientific community has done a poor job in un-
equivocally identifying the benefits of oxygen ther-
apy. . . especially ambulatory oxygen therapy. A rea-
sonably compelling case can be made for each of the
contentions that ambulatory oxygen is a greatly un-
derused and a greatly overused treatment modality.
The argument that too few patients receive
ambulatory oxygen is based on the observation
that giving supplemental oxygen during exercise to
COPD patients substantially improves exercise tol-
erance. . . even in patients who do not demonstrate
decreases in oxygen saturation generally considered
clinically important.55 The mechanism of this bene-
fit apparently involves carotid body inhibition lead-
ing to reduction in pulmonary ventilation and res-
piratory rate at a given level of exercise that, in
turn, results in decreased dynamic hyperinflation
and dyspnea.55 The magnitude of increase in exer-
cise tolerance engendered by supplemental oxygen
is generally greater than that conferred by bron-
chodilator therapy. As exercise intolerance is the
chief complaint of many (if not most) COPD pa-
tients, provision of ambulatory oxygen to a large
number of those not meeting current criteria for
LTOT can be seen as reasonable.
The contrary argument can just as easily be
made. Our current mandate for provision of LTOT
is founded on two studies, the Nocturnal Oxygen
Therapy Trial (NOTT)56 and the Medical Research
Council (MRC) study57 (which involved 203 and 87
patients, respectively), which showed substantial
survival advantage when COPD patients who mani-
fested severe hypoxemia while at rest received sup-
plemental oxygen. Collectively, these studies sug-
gested that the more hours per day that these pa-
tients received oxygen, the better the survival out-
come. It should be appreciated that studies show-
ing that an intervention improves survival carry spe-
cial weight; it is difficult to deny patients a ther-
apy if they will die sooner without it. . . even if
the cost to society is large! However, in the years
since these studies have been published (in 1980 and
1981), no studies demonstrating positive effects of
oxygen therapy on survival have appeared. Specifi-
cally, no study has shown that long-term outcomes
are improved when patients are provided with am-
bulatory oxygen. Of relevance, anecdotal reports
have suggested that many patients currently receiv-
ing ambulatory oxygen supplies use them so little
that it is hard to believe that much benefit ac-
crues.
It can further be posited that the only way to
resolve these conflicting arguments is to perform
large-scale trials to establish the long-term bene-
fit of ambulatory oxygen. Two distinct studies can
be conceptualized. In one, patients meeting cur-
rent criteria for LTOT could be randomized to re-
ceive either stationary oxygen plus ambulatory oxy-
gen or stationary oxygen alone. In the other, pa-
tients not meeting current criteria for provision of
supplemental oxygen at rest could be randomized
to receive either ambulatory oxygen or no oxygen
supplementation (whether inclusion criteria should
include clinically appreciable desaturation with ex-
ercise can be argued). In either study, it can be seen
that participants receiving ambulatory oxygen will
likely avoid no more than perhaps an average of 2
or 3 hours of hypoxemia per day. This is considerably
less than the difference in daily oxygen use between
the groups studied in the NOTT and MRC trials. . . it
makes sense to base studies of ambulatory oxygen
on the assumption that the impact on survival will
be smaller. A rough sample size calculation based
on a 5% absolute (and 17% relative) survival differ-
ence in a 4 year trial (assuming α = 0.05 and power
= 0.9) indicates that 3500 patients would have to be
studied. . . a daunting undertaking.
Surprisingly, a trial of similar proportions is be-
ing organized by the National Institutes of Health in
the United States. Recognizing the information gaps
that exist in the provision of long-term oxygen58,
a request for applicants for a study dubbed the
Long-Term Oxygen Therapy Trial (LOTT) was issued
in November 2005. The stated plan was to recruit
20 sites that would each be tasked with enrolling
250 subjects (a total of 5000 among sites). Although
the fine details of the study were to be left to the
investigators selected to perform the trial, the ba-
sic study design was laid out. Selected participants
would be COPD patients with poor prognosis who
do not meet current criteria for hypoxemia at rest
allowing them to qualify for LTOT. They would be
randomized to either usual care or usual care plus
LTOT, including both stationary and ambulatory sup-
plies. The primary outcome measure in this 5 year
trial (with an average follow-up of approximately
3.5 years) would be survival. It is proposed that this
study will begin recruitment in 2007.
Long-term oxygen therapy research has been rel-
atively quiescent over the past 25 years. Given the
cost and potential effectiveness of this therapy, this
lack of attention seems inappropriate. This situa-
tion, though, appears to be changing.
Conclusions
Ambulatory oxygen is well-established therapy but,
surprisingly, firm scientifically-based indications for
its use have not been established. This review has
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explored the situations in the United Kingdom and
the United States and has found some similarities
and some differences. Review of the current status
of ambulatory oxygen in other countries would be
of interest. It is also clear that research aimed at
defining the benefits that can be expected from am-
bulatory oxygen therapy, both in the continuously
hypoxemic patient and the patient with isolated hy-
poxemia on exertion, is needed.
Conflict of interest statement
N Ambrosino, R Goldstein, MDL Morgan M Rudolf, S
Singh and PJ Wijkstra have no conflict of interest to
declare.
R Casaburi is consultant for Inogen, Inc.
G Ford has received honoraria and travel ex-
penses for speaking at scientific meetings and con-
tinuing medical education courses from GSK. He
has received research funding from GSK, Altana
Pharma (AC), AstraZeneca (AZ), Boehringer Ingel-
heim, Canada, Limited (BICL). He has also received
honoraria and travel expenses for participating on
medical advisory boards for various pharmaceutical
companies (GSK, AZ, BICL, AC, Pfizer Canada and
Abbott Canada).
References
1. Goldstein RS, Gort EH, Stubbing D, Avendano MA, Guyatt
GH. Randomised controlled trial of respiratory rehabilita-
tion.
2. Wijkstra PJ, van Altena R, Kraan J, Otten V, Postma DS,
Koeter GH. Quality of life in patients with chronic ob-
structive pulmonary disease improves after rehabilitation
at home. Eur Respir J 1994; 7(2):269---273.
3. Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins
J, Shiels K et al. Results at 1 year of outpatient multidisci-
plinary pulmonary rehabilitation: a randomised controlled
trial. Lancet 2000; 355(9201):362---368.
4. Lacasse Y, Wong E, Guyatt GH, King D, Cook DJ, Gold-
stein RS. Meta-analysis of respiratory rehabilitation in
chronic obstructive pulmonary disease. Lancet 1996;
348(9035):1115---1119.
5. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd
SS. Global strategy for the diagnosis, management, and
prevention of chronic obstructive pulmonary disease.
NHLBI/WHO Global Initiative for Chronic Obstructive Lung
Disease (GOLD) Workshop summary. Am J Respir Crit Care
Med 2001; 163(5):1256---1276.
6. National Institute Clinical Excellence clinical guideline.
Pulmonary rehabilitation service for patients with COPD.
2006. http://www.nice.org.uk
7. BTS consortium 2001
8. Pitta F, Troosters T, Probst VS et al. Physical activ-
ity and hospitalization for exacerbation of COPD. Chest
2006;129:536---44.
9. Garcia-Ayermich J, Farrero E, Felez MA et al. Risk fac-
tors of readmission to hospital for a COPD exacerbation:
a prospective study. Thorax 2003;58:100---5.
10. Garcia-Ayermich J, Lange P, Benet M et al. Regular phys-
ical activity reduces hospital admission and mortality
in chronic obstructive pulmonary disease: a population
based cohort study. Thorax 2006 Sep;61:772---8. Epub 2006
May 31
11. Man WD, Polkey MI, Donaldson N et al. Community pul-
monary rehabilitation after hospitalisation for acute exac-
erbations of chronic obstructive pulmonary disease: ran-
domised controlled study. BMJ 2004;329(7476):1209. Epub
2004 Oct 25
12. Lacasse Y, Brosseau L, Milne S, Martin S, Wong E, Guy-
att GH, Goldstein RS. Pulmonary rehabilitation in chronic
obstructive pulmonary disease (Cochrane Review). In: the
Cochrane Database Syst Rev 3, 2002. Oxford: Update Soft-
ware. 3CD003793
13. O' Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk
D, Balter M, Ford G, Gervais A, Goldstein R, Hodder R, Mal-
tais F, Road J. Canadian Thoracic Society recommendations
for management of chronic obstructive pulmonary disease
--- 2003. Can Respir J 2003;10:1A---71A
14. Bodenheimer T, Wagner EH, Grumbach K. Improving pri-
mary care for patients with chronic illness JAMA 2002; 288:
1775---1779
15. Bodenheimer T, Wagner EH, Grumbach K et al. Improving
primary care for patients with chronic illness: the chronic
care model Part 2. JAMA 2002; 288: 1909---1914
16. Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupre A, Be-
gin R et al. Reduction of hospital utilization in patients
with chronic obstructive pulmonary disease: a disease-
specific self-management intervention. Arch Intern Med
2003;163:585---91
17. Lorig K, Holman HR, Sobel D, Laurent D, González V, Mi-
nor M. Living a healthy life with chronic conditions. 2nd
edition. Palo Alto, CA: Bull Publications; 2000.
18. Lorig KR, Sobel DS, Stewart AL, Brown BW Jr., Ban-
dura A, Ritter P, Gonzalez VM, Laurent DD, Holman
HR. Evidence suggesting that a chronic disease self-
management program can improve health status while
reducing hospitalization: a randomized trial. Med Care
1999;37:5---14.
19. Lorig KR, Ritter P, Stewart AL, Sobel DS, Brown BW Jr.,
Bandura A, Gonzalez VM, Laurent DD, Holman HR. Chronic
disease self-management program: 2-year health status
and health care utilization outcomes. Med Care 2001;
39:1217---1223.
20. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N,
Bourbeau J et al. American Thoracic Society/European
Respiratory Society statement on pulmonary rehabilita-
tion. Am J Respir Crit Care Med 2006; 173(12): 1390---1413.
21. Lotters F, van Tol B, Kwakkel G, Gosselink R. Effects of con-
trolled inspiratory muscle training in patients with COPD:
a meta-analysis. Eur Respir J 2002; 20(3):570---576.
22. Dekhuijzen PN, Folgering HT, van Herwaarden CL. Target-
flow inspiratory muscle training during pulmonary re-
habilitation in patients with COPD. Chest 1991; 99(1):
128---133.
23. Wanke T, Formanek D, Lahrmann H, Brath H, Wild M, Wag-
ner C et al. Effects of combined inspiratory muscle and
cycle ergometer training on exercise performance in pa-
tients with COPD. Eur Respir J 1994; 7(12):2205---2211.
24. Weiner P, Azgad Y, Ganam R. Inspiratory muscle training
combined with general exercise reconditioning in patients
with COPD. Chest 1992; 102(5):1351---1356.
25. Berry MJ, Adair NE, Sevensky KS, Quinby A, Lever HM. In-
spiratory muscle training and whole-body reconditioning
S26 N. Ambrosino et al.
in chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 1996; 153(6 Pt 1):1812---1816.
26. Larson JL, Covey MK, Wirtz SE, Berry JK, Alex CG, Langbein
WE et al. Cycle ergometer and inspiratory muscle training
in chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 1999; 160(2):500---507.
27. Lacasse Y, Guyatt GH, Goldstein RS. The components of a
respiratory rehabilitation program: a systematic overview.
Chest 1997; 111(4):1077---1088.
28. Rooyackers JM, Dekhuijzen PN, van Herwaarden CL, Fol-
gering HT. Training with supplemental oxygen in patients
with COPD and hypoxaemia at peak exercise. Eur Respir J
1997; 10(6):1278---1284.
29. Garrod R, Paul EA, Wedzicha JA. Supplemental oxygen dur-
ing pulmonary rehabilitation in patients with COPD with
exercise hypoxaemia. Thorax 2000; 55(7):539---543.
30. Emtner M, Porszasz J, Burns M, Somfay A, Casaburi R. Ben-
efits of supplemental oxygen in exercise training in nonhy-
poxemic chronic obstructive pulmonary disease patients.
Am J Respir Crit Care Med 2003; 168(9):1034---1042.
31. van Helvoort HA, Heijdra YF, Heunks LM, Meijer PL, Ruiten-
beek W, Thijs HM et al. Supplemental oxygen prevents
exercise-induced oxidative stress in muscle-wasted pa-
tients with chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2006; 173(10):1122---1129.
32. Keilty SE, Ponte J, Fleming TA, Moxham J. Effect of inspi-
ratory pressure support on exercise tolerance and breath-
lessness in patients with severe stable chronic obstructive
pulmonary disease. Thorax 1994; 49(10):990---994.
33. Maltais F, Reissmann H, Gottfried SB. Pressure support re-
duces inspiratory effort and dyspnea during exercise in
chronic airflow obstruction. Am J Respir Crit Care Med
1995; 151(4):1027---1033.
34. ' t Hul A, Gosselink R, Hollander P, Postmus P, Kwakkel G.
Training with inspiratory pressure support in patients with
severe COPD. Eur Respir J 2006; 27(1):65---72.
35. Garrod R, Mikelsons C, Paul EA, Wedzicha JA. Randomized
controlled trial of domiciliary noninvasive positive pres-
sure ventilation and physical training in severe chronic ob-
structive pulmonary disease. Am J Respir Crit Care Med
2000; 162(4 Pt 1):1335---1341.
36. Neder JA, Sword D, Ward SA, Mackay E, Cochrane LM, Clark
CJ. Home based neuromuscular electrical stimulation as a
new rehabilitative strategy for severely disabled patients
with chronic obstructive pulmonary disease (COPD). Tho-
rax 2002; 57(4):333---337.
37. Bourjeily-Habr G, Rochester CL, Palermo F, Snyder P, Mohs-
enin V. Randomised controlled trial of transcutaneous elec-
trical muscle stimulation of the lower extremities in pa-
tients with chronic obstructive pulmonary disease. Thorax
2002; 57(12):1045---1049.
38. Zanotti E, Felicetti G, Maini M, Fracchia C. Peripheral mus-
cle strength training in bed-bound patients with COPD re-
ceiving mechanical ventilation: effect of electrical stimu-
lation. Chest 2003; 124(1):292---296.
39. Vivodtzev I, Pepin JL, Vottero G, Mayer V, Porsin B, Levy
P et al. Improvement in quadriceps strength and dysp-
nea in daily tasks after 1 month of electrical stimulation
in severely deconditioned and malnourished COPD. Chest
2006; 129(6):1540---1548.
40. Royal College of Physicians of London EU. Domiciliary Oxy-
gen Therapy Services. 1---49. 1999.
41. British Thoracic Society, http:www.brit-thoracic.org.uk/c2/
uploads/clinical%20adultoxygenjan06.pdf. Clinical Com-
ponent for the Home Oxygen Service in England and Wales.
2005.
42. Somfay A, Porszasz J, Lee SM, Casaburi R. Dose-response
effect of oxygen on hyperinflation and exercise endurance
in nonhypoxaemic COPD patients. Eur Respir J 2001;
18(1):77---84.
43. Stevenson NJ, Calverley PM. Effect of oxygen on recovery
from maximal exercise in patients with chronic obstructive
pulmonary disease. Thorax 2004; 59(8):668---672.
44. Bradley JM, O' Neill B. Short-term ambulatory oxygen for
chronic obstructive pulmonary disease. Cochrane Database
Syst Rev 2005;(4):CD004356.
45. Eaton T, Garrett JE, Young P, Fergusson W, Kolbe J, Rud-
kin S et al. Ambulatory oxygen improves quality of life of
COPD patients: a randomised controlled study. Eur Respir
J 2002; 20(2):306---312.
46. Lacasse Y, Lecours R, Pelletier C, Begin R, Maltais F. Ran-
domised trial of ambulatory oxygen in oxygen-dependent
COPD. Eur Respir J 2005; 25(6):1032---1038.
47. (11) Eaton T, Fergusson W, Kolbe J, Lewis CA, West
T. Short-burst oxygen therapy for COPD patients: a 6-
month randomised, controlled study. Eur Respir J 2006;
27(4):697---704.
48. (12) Lock SH, Paul EA, Rudd RM, Wedzicha JA. Portable
oxygen therapy: assessment and usage. Respir Med 1991;
85(5):407---412.
49. Silverman BG, Gross TP, Babish JD. Home oxygen ther-
apy in Medicare beneficiaries, 1991 and 1992. Chest 1997;
112(2):380---386.
50. Croxton TL, Weinmann GG, Senior RM, Wise RA, Crapo
JD, Buist AS. Clinical research in chronic obstructive pul-
monary disease: needs and opportunities. Am J Respir Crit
Care Med 2003; 167(8):1142---1149.
51. Pierson DJ. Controversies in home respiratory care: con-
ference summary. Respir Care 1994; 39(4):294---308
52. Chaney JC, Jones K, Grathwohl K, Olivier KN. Implementa-
tion of an oxygen therapy clinic to manage users of long-
term oxygen therapy. Chest 2002; 122(5):1661---1667.
53. O' Donohue WJ, Jr. Effect of oxygen therapy on increasing
arterial oxygen tension in hypoxemic patients with stable
chronic obstructive pulmonary disease while breathing am-
bient air. Chest 1991; 100(4):968---97
54. Doherty DE, Petty TL, Bailey W, Carlin B, Casaburi R,
Christopher K et al. Recommendations of the 6th long-term
oxygen therapy consensus conference. Respir Care 2006;
51(5):519---525.
55. Somfay A, Porszasz J, Lee SM, Casaburi R. Effect of hy-
peroxia on gas exchange and lactate kinetics following ex-
ercise onset in nonhypoxemic COPD patients. Chest 2002;
121(2):393---400.
56. Continuous or nocturnal oxygen therapy in hypoxemic
chronic obstructive lung disease: a clinical trial. Noctur-
nal Oxygen Therapy Trial Group. Ann Intern Med 1980;
93(3):391---398.
57. Long term domiciliary oxygen therapy in chronic hypoxic
cor pulmonale complicating chronic bronchitis and em-
physema. Report of the Medical Research Council Working
Party. Lancet 1981; 1(8222):681---686.
58. Croxton TL, Bailey WC. Long-term oxygen treatment in
chronic obstructive pulmonary disease: recommendations
for future research: an NHLBI workshop report. Am J Respir
Crit Care Med 2006; 174(4):373---378.
